SMT202400463T1 - Composizioni e metodi per il trattamento di omocistinuria - Google Patents

Composizioni e metodi per il trattamento di omocistinuria

Info

Publication number
SMT202400463T1
SMT202400463T1 SM20240463T SMT202400463T SMT202400463T1 SM T202400463 T1 SMT202400463 T1 SM T202400463T1 SM 20240463 T SM20240463 T SM 20240463T SM T202400463 T SMT202400463 T SM T202400463T SM T202400463 T1 SMT202400463 T1 SM T202400463T1
Authority
SM
San Marino
Prior art keywords
homocystinuria
compositions
treatment
methods
Prior art date
Application number
SM20240463T
Other languages
English (en)
Italian (it)
Inventor
Tomas Majtan
Erez Bublil
Jan P Kraus
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/935,690 external-priority patent/US9675678B2/en
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Publication of SMT202400463T1 publication Critical patent/SMT202400463T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SM20240463T 2015-11-09 2016-11-09 Composizioni e metodi per il trattamento di omocistinuria SMT202400463T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/935,690 US9675678B2 (en) 2013-01-29 2015-11-09 Compositions and methods for treatment of homocystinuria
EP21204193.3A EP3998067B1 (en) 2015-11-09 2016-11-09 Compositions and methods for treatment of homocystinuria

Publications (1)

Publication Number Publication Date
SMT202400463T1 true SMT202400463T1 (it) 2025-01-14

Family

ID=58696136

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20240463T SMT202400463T1 (it) 2015-11-09 2016-11-09 Composizioni e metodi per il trattamento di omocistinuria
SM20220151T SMT202200151T1 (it) 2015-11-09 2016-11-09 Composizioni e metodi per l’uso nel trattamento di omocistinuria.

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM20220151T SMT202200151T1 (it) 2015-11-09 2016-11-09 Composizioni e metodi per l’uso nel trattamento di omocistinuria.

Country Status (26)

Country Link
US (3) US11077175B2 (enExample)
EP (3) EP4487914A3 (enExample)
JP (2) JP7009364B2 (enExample)
KR (1) KR102819396B1 (enExample)
CN (2) CN115920016A (enExample)
AU (2) AU2016354030B2 (enExample)
BR (1) BR112018007768A2 (enExample)
CA (1) CA3001625A1 (enExample)
CY (1) CY1125113T1 (enExample)
DK (2) DK3998067T3 (enExample)
ES (2) ES2909914T3 (enExample)
FI (1) FI3998067T3 (enExample)
HR (2) HRP20220407T1 (enExample)
HU (2) HUE058749T2 (enExample)
IL (2) IL258487B2 (enExample)
LT (2) LT3373922T (enExample)
MX (1) MX2018005312A (enExample)
NZ (1) NZ741552A (enExample)
PL (2) PL3998067T3 (enExample)
PT (2) PT3998067T (enExample)
RS (2) RS66106B1 (enExample)
SG (1) SG10201912972SA (enExample)
SI (2) SI3998067T1 (enExample)
SM (2) SMT202400463T1 (enExample)
WO (1) WO2017083327A1 (enExample)
ZA (1) ZA201802376B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
BR112018007768A2 (pt) 2015-11-09 2018-10-23 Univ Colorado Regents composições e métodos para tratamento de homocistinúria
JP7146897B2 (ja) * 2017-04-17 2022-10-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト ホモシスチン尿症の治療のための酵素補充療法の最適化
DK3990005T3 (da) * 2019-06-26 2025-12-08 Travere Therapeutics Switzerland Gmbh Pegyleret cystathioninbetasynthase til enzymterapi til behandling af homocystinuri
EP4025243A4 (en) * 2019-09-03 2023-09-27 Travere Therapeutics Switzerland GmbH CYSTATHIONINE BETA-SYNTHASE ENZYMA THERAPY FOR THE TREATMENT OF HIGH HOMOCYSTEINE LEVELS

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS555429A (en) * 1978-06-23 1980-01-16 Nissan Motor Co Ltd Pressure regulator for fuel injection type gasoline engine
JPS5576559A (en) 1978-12-01 1980-06-09 Chiyou Lsi Gijutsu Kenkyu Kumiai Electron beam fine adjusting device
US5656425A (en) 1993-08-17 1997-08-12 Regents Of The University Of Colorado Screening for mutations by expressing cDNA segments
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
EP1221615A2 (en) 1995-04-25 2002-07-10 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
CN100335503C (zh) 1998-04-28 2007-09-05 应用研究系统Ars股份公司 多元醇干扰素β偶联物
US6174696B1 (en) 1999-11-12 2001-01-16 Genzyme Corporation Method for the determination of homocysteine
WO2001002600A2 (en) 1999-07-06 2001-01-11 General Atomics Detection of analytes using attenuated enzymes
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US20030091543A1 (en) 2001-10-26 2003-05-15 Klein Matthew B. Therapeutic cell preparation grafts and methods of use thereof
US7485307B2 (en) 2002-06-17 2009-02-03 The Regents Of The University Of Colorado Human cystathionine β-synthase variants and methods of production thereof
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
EP1396537A1 (en) * 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
US20050036981A1 (en) 2003-07-31 2005-02-17 Shigeo Yagi USE OF PLP WITH PEG-rMETase IN VIVO FOR ENHANCED EFFICACY
CN1552905A (zh) 2003-12-18 2004-12-08 中国农业科学院茶叶研究所 一类茶树胱硫醚-γ-合成酶特异表达序列标签及其生物芯片
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070010492A1 (en) 2005-07-11 2007-01-11 Generale Robert J Composition and method for reducing homocysteine caused by drugs containing methyl compounds
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
JP6041454B2 (ja) * 2007-03-15 2016-12-07 株式会社 Ｄｎａセキュリティー研究所 Ｄｎａ含有インク組成物
JP5074146B2 (ja) 2007-03-30 2012-11-14 オリンパス株式会社 カプセル型医療装置
CN101322840A (zh) 2008-05-28 2008-12-17 中国人民解放军军事医学科学院卫生学环境医学研究所 一种人胱硫醚β-合成酶重组蛋白及应用
EP2470568A2 (en) 2009-08-29 2012-07-04 Abbott Laboratories Therapeutic dll4 binding proteins
WO2011097381A2 (en) 2010-02-04 2011-08-11 The Board Of Regents Of Use University Of Texas System Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
CA2803668A1 (en) 2010-07-01 2012-01-05 Isis Innovation Limited Treatment of cognitive disorders
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
WO2015033279A1 (en) * 2013-09-04 2015-03-12 Mahesh Kandula Compositions and methods for the treatment of homocystinuria
EP3325496B1 (en) 2015-07-24 2024-02-07 Hanmi Pharm. Co., Ltd. Method of preparing physiologically active polypeptide conjugate
BR112018007768A2 (pt) 2015-11-09 2018-10-23 Univ Colorado Regents composições e métodos para tratamento de homocistinúria
JP7146897B2 (ja) * 2017-04-17 2022-10-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト ホモシスチン尿症の治療のための酵素補充療法の最適化
JP7002314B2 (ja) * 2017-12-13 2022-02-10 株式会社ブリヂストン 空気入りタイヤ
DK3990005T3 (da) 2019-06-26 2025-12-08 Travere Therapeutics Switzerland Gmbh Pegyleret cystathioninbetasynthase til enzymterapi til behandling af homocystinuri
EP4025243A4 (en) 2019-09-03 2023-09-27 Travere Therapeutics Switzerland GmbH CYSTATHIONINE BETA-SYNTHASE ENZYMA THERAPY FOR THE TREATMENT OF HIGH HOMOCYSTEINE LEVELS

Also Published As

Publication number Publication date
RS63070B1 (sr) 2022-04-29
PL3998067T3 (pl) 2025-01-07
HUE068830T2 (hu) 2025-01-28
US11077175B2 (en) 2021-08-03
JP7482914B2 (ja) 2024-05-14
AU2022287540A1 (en) 2023-02-02
CN115920016A (zh) 2023-04-07
EP4487914A3 (en) 2025-03-26
JP2018532763A (ja) 2018-11-08
EP3998067A1 (en) 2022-05-18
SMT202200151T1 (it) 2022-05-12
AU2022287540B2 (en) 2025-02-27
CA3001625A1 (en) 2017-05-18
KR20180074703A (ko) 2018-07-03
US20220125896A1 (en) 2022-04-28
NZ741552A (en) 2022-04-29
AU2016354030B2 (en) 2022-09-15
RS66106B1 (sr) 2024-11-29
PT3998067T (pt) 2024-11-04
EP4487914A2 (en) 2025-01-08
EP3373922A1 (en) 2018-09-19
HK1258502A1 (en) 2019-11-15
HRP20220407T1 (hr) 2022-05-27
DK3998067T3 (da) 2024-10-28
IL302198A (en) 2023-06-01
MX2018005312A (es) 2018-08-15
HUE058749T2 (hu) 2022-09-28
LT3998067T (lt) 2024-11-25
JP2022050589A (ja) 2022-03-30
KR102819396B1 (ko) 2025-06-12
IL258487B1 (en) 2023-05-01
HRP20241491T1 (hr) 2025-01-03
US11771745B2 (en) 2023-10-03
IL258487A (en) 2018-05-31
EP3373922B1 (en) 2022-01-05
PT3373922T (pt) 2022-03-28
ES2994256T3 (en) 2025-01-21
PL3373922T3 (pl) 2022-05-02
SI3373922T1 (sl) 2022-05-31
LT3373922T (lt) 2022-04-11
EP3373922A4 (en) 2019-05-15
US20240091325A1 (en) 2024-03-21
ES2909914T3 (es) 2022-05-10
US20200276282A1 (en) 2020-09-03
DK3373922T3 (da) 2022-03-28
FI3998067T3 (fi) 2024-10-31
WO2017083327A1 (en) 2017-05-18
SI3998067T1 (sl) 2025-03-31
ZA201802376B (en) 2020-11-25
AU2016354030A1 (en) 2018-05-10
CN108472277A (zh) 2018-08-31
JP7009364B2 (ja) 2022-02-10
SG10201912972SA (en) 2020-03-30
CY1125113T1 (el) 2024-02-16
EP3998067B1 (en) 2024-09-11
BR112018007768A2 (pt) 2018-10-23
IL258487B2 (en) 2023-09-01
US12194082B2 (en) 2025-01-14

Similar Documents

Publication Publication Date Title
IL258955B1 (en) Cancer treatment preparations and methods
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
PL3288581T3 (pl) Sposób leczenia nowotworu
PL3377516T3 (pl) Kompozycja do leczenia nowotworu
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3212226T3 (da) Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
IL257784A (en) Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
IL254779A0 (en) Methods of administering glutaminase inhibitors
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3324932T3 (da) Sammensætninger og fremgangsmåder for nanopartikel lyofile former
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
PL3189074T3 (pl) Kompozycje oraz sposoby leczenia i zapobiegania zapaleniom
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
PL3393468T3 (pl) Metody leczenia niedoboru odporności
DK3212776T3 (da) Sammensætninger og fremgangsmåder i forbindelse med beta-glucosidase
LT3307267T (lt) Išsėtinės sklerozės gydymas
DK3261609T3 (da) Sammensætninger omfattende ravsyre og akonitsyre
ZA201802376B (en) Compositions and methods for treatment of homocystinuria
DK3169405T3 (da) Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme
DK3122743T3 (da) Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme
EP3325002C0 (en) COMBINED THERAPEUTIC COMPOSITIONS